





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING D	ATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	ATTORNEY DOCKET NO. CONFIRMATION NO.	
09/665,728 09/20/2000		000	Lawrence W. Stanton	SCIOS.013A	8743	
20995	7590	02/04/2003				
	IARTENS OL	SON & BEA	EXAMINER			
2040 MAIN S FOURTEEN	TH FLOOR		O HARA, EILEEN B			
IRVINE, CA	92614			ART UNIT	PAPER NUMBER	
				1646	16	
				DATE MAILED: 02/04/2003	;	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N .	Applicant(s)	
Ádvisory Action	09/665,728	STANTON ET AL.	
V	Examiner	Art Unit	
	Eileen B. O'Hara	1646	•
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orresp ndence address	
THE REPLY FILED 27 December 2002 FAILS TO PLAC Therefore, further action by the applicant is required to av final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment which	tion. A proper reply to a	
<u> </u>	PLY [check either a) or b)]		
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A		ta Alas Cardinata Atau da Atau da Araba	
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the control of	ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH date on which the petition under 37 CFI f extension and the corresponding amount he shortened statutory period for reply on the later than three months after the mail	or date of the final rejection. E FINAL REJECTION. See MPER R 1.136(a) and the appropriate extended the following the fee. The appropriate extended the fee. The appropriate extended the final office actions are the final office actions.	ension ension ension
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR	R 1.191(d)), to avoid dismissal of	riod set forth in the appeal.	
2. The proposed amendment(s) will not be entered be	cause:		
(a) they raise new issues that would require furthe	·	ee NOTE below);	
(b) they raise the issue of new matter (see Note be	•		
(c) they are not deemed to place the application in issues for appeal; and/or	better form for appeal by mater	ially reducing or simplifying	the
(d) ☐ they present additional claims without cancelingNOTE:	ng a corresponding number of fi	nally rejected claims.	
3. Applicant's reply has overcome the following rejection	on(s): <u>See Continuation Sheet</u> .		
4. Newly proposed or amended claim(s) would be canceling the non-allowable claim(s).	pe allowable if submitted in a se	parate, timely filed amendme	eņt
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: See	reconsideration has been consideration Sheet.	lered but does NOT place th	е
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	use it is not directed SOLELY to	issues which were newly	
7. For purposes of Appeal, the proposed amendment (explanation of how the new or amended claims wo	s) a)⊡ will not be entered or b)[uld be rejected is provided belov	☑ will be entered and an vor appended.	
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed:			
Claim(s) objected to:		·	
Claim(s) rejected: <u>1-8 and 30-33</u> .			
Claim(s) withdrawn from consideration:			
8. The proposed drawing correction filed on is a	ı)□ approved or b)□ disappr	oved by the Examiner.	
9. Note the attached Information Disclosure Statement			
10.⊠ Other: <u>See Continuation Sheet</u>			





Continuation of 3/Applicant's reply has overcome the following rejection(s): rejections under 35 U.S.C. 112, first paragraph for written description.

Continuation of 5. does NOT place the application in condition for allowance because: Applicants' arguments have been fully considered but are not deemed persuasive. Although the polypeptide encoded by the claimed polynucleotide sequence may show elevated plasma levels that correspond to the up-regulation of the nucleic acid in the myocardial infarction model, it is not predictable that this would be the case for the protein. Increase in transcript levels do not necessarily correlate with increase in protein produced. Additionally, Applicants assume that the encoded protein is secreted because of the presence of a predicted signal sequence; however many proteins that have signal sequences are membrane bound proteins (for example receptors, hedgehog proteins and many cytokines as well as proteins that localize to intracellular membranes, i.e. Golgi apparatus, etc.) and would not be found in plasma. The claimed invention does not have utility in its current state. If evidence that the protein encoded by the polynucleotide of SEQ ID NO: 2 could be detected at increased levels in the myocardial infarction disease model in plasma, the utility rejection might be overcome. Therefore, for reasons of record in the previous Office Actions and the above, the rejections are maintained.

Continuation of 10. Other: On page 4 of the After Final Amendment Applicants state that they provide copies of pages 45-56 of the specification and a copy of the post card provided when the application was filed. However, these materials were not present in the submitted paperwork. It is requested that Applicants submit these materials in their next response.

LORRAINE SPECTOR PRIMARY EXAMINER